[A18-71] Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2019
Commission awarded on 29.10.2018 by the Federal Joint Committee (G-BA).
Head and nerves
Prophylaxis of migraine
Patients who do not respond to other drug classes, or do not tolerate them, or for whom these are unsuitable: indication of considerable added benefit. Patients with other treatment options: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A21-58||Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)||Commission completed|
Federal Joint Committee (G-BA)
2019-09-19 A G-BA decision was published.